Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254505 | 0.82 | AOC3 (0.55) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| Trimethyldiphenylpropylamine SCHEMBL25589 | 0.81 | HRH1 (0.52) | AOC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL13619949 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13433805 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL8425086 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL75953 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3097213 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL477671 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13433806 | 0.79 | LMNA (0.60) | AOC3LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL11238622 | 0.78 | LMNA (0.46) | AOC3LMNAKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0604363-B1 | Stable solutions of accelerators for epoxy resins | VANTICO AG (CH) | 2003-02-12 | — | — | EP | claimed |
| EP-0604363-A2 | Stable solutions of accelerators for epoxy resins | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | claimed |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| EP-0604363-B1 | Stable solutions of accelerators for epoxy resins | VANTICO AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| EP-0604363-A2 | Stable solutions of accelerators for epoxy resins | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | AOC3 1273/4885LMNA 2026/4885KDM4E 599/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | AOC3 571/4885LMNA 3185/4885KDM4E 2664/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | AOC3 404/4885LMNA 3075/4885KDM4E 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.